JPH0130807B2 - - Google Patents

Info

Publication number: JPH0130807B2
Authority: JP; Japan
Prior art keywords: parts; sodium fluoride; talc; matrix; present
Prior art date: 1983-08-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP59100727A

Other languages

English (en)

Japanese (ja)

Other versions

JPS6042323A (ja

Inventor

Beiri Uorusudorufu Niiru

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-08-11

Filing date

1984-05-21

Publication date

1989-06-22

1984-05-21 Application filed by Individual filed Critical Individual

1985-03-06 Publication of JPS6042323A publication Critical patent/JPS6042323A/ja

1989-06-22 Publication of JPH0130807B2 publication Critical patent/JPH0130807B2/ja

Status Granted legal-status Critical Current

Links

PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 65
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 34
239000011775 sodium fluoride Substances 0.000 claims description 32
235000013024 sodium fluoride Nutrition 0.000 claims description 32
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 30
239000004203 carnauba wax Substances 0.000 claims description 23
235000013869 carnauba wax Nutrition 0.000 claims description 23
239000000454 talc Substances 0.000 claims description 20
229910052623 talc Inorganic materials 0.000 claims description 20
239000011159 matrix material Substances 0.000 claims description 18
235000000346 sugar Nutrition 0.000 claims description 16
235000019359 magnesium stearate Nutrition 0.000 claims description 15
235000012222 talc Nutrition 0.000 claims description 9
239000002245 particle Substances 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 7
229940079593 drug Drugs 0.000 claims description 5
238000000034 method Methods 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 4
239000006185 dispersion Substances 0.000 claims description 3
239000002270 dispersing agent Substances 0.000 claims 3
239000003826 tablet Substances 0.000 description 33
238000011282 treatment Methods 0.000 description 14
239000004615 ingredient Substances 0.000 description 12
239000001993 wax Substances 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 7
208000020084 Bone disease Diseases 0.000 description 5
208000001132 Osteoporosis Diseases 0.000 description 5
239000003513 alkali Substances 0.000 description 5
150000002222 fluorine compounds Chemical class 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000002253 acid Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
-1 fluoride ions Chemical class 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 1
102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
208000013038 Hypocalcemia Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007950 delayed release tablet Substances 0.000 description 1
208000002925 dental caries Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000029142 excretion Effects 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007970 homogeneous dispersion Substances 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000000705 hypocalcaemia Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
230000036284 oxygen consumption Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP59100727A 1983-08-11 1984-05-21 フツ化物錠剤とその製法 Granted JPS6042323A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US52201483A	1983-08-11	1983-08-11
US522014		1983-08-11

Publications (2)

Publication Number	Publication Date
JPS6042323A JPS6042323A (ja)	1985-03-06
JPH0130807B2 true JPH0130807B2 (fr)	1989-06-22

Family

ID=24079076

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP59100727A Granted JPS6042323A (ja)	1983-08-11	1984-05-21	フツ化物錠剤とその製法

Country Status (4)

Country	Link
JP (1)	JPS6042323A (fr)
CA (1)	CA1219219A (fr)
CH (1)	CH655851A5 (fr)
DE (1)	DE3343253A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0289314B1 (fr) *	1987-04-28	1994-10-12	Roche Diagnostics GmbH	Emploi de IGF-II pour le traitement de désordres des os
AU2003225649C1 (en) *	2003-03-04	2009-10-22	Nostrum Pharmaceuticals, Inc.	Control release formulation containing a hydrophobic material as the sustained release agent
CN103439377B (zh) *	2013-08-13	2015-12-09	江苏大学	一种NaF释放的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2805977A (en) *	1955-01-04	1957-09-10	Smith Kline French Lab	Sustained release pharmaceutical preparation
DE2630326C2 (de) *	1976-07-06	1983-07-21	"Gebro" G. Broschek Kg, Chemisch-Pharmazeutische Fabrik, 6391 Fieberbrunn, Tirol	Präparat zur Behandlung der Osteoporose und seine Herstellung

1983
- 1983-11-30 DE DE19833343253 patent/DE3343253A1/de active Granted
- 1983-12-14 CH CH6669/83A patent/CH655851A5/de not_active IP Right Cessation
1984
- 1984-01-05 CA CA000444788A patent/CA1219219A/fr not_active Expired
- 1984-05-21 JP JP59100727A patent/JPS6042323A/ja active Granted

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS=1974 *
CHEMICAL ABSTRACTS=1975 *
CHEMICAL ABSTRACTS=1976 *
CHEMICAL ABSTRACTS=1981 *

Also Published As

Publication number	Publication date
CA1219219A (fr)	1987-03-17
CH655851A5 (de)	1986-05-30
DE3343253A1 (de)	1985-02-21
JPS6042323A (ja)	1985-03-06
DE3343253C2 (fr)	1989-07-20

Legal Events

Date	Code	Title	Description
2004-05-21	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
DE69911240T2 (de)	2004-07-15	Zusammensetzungen, enthaltend mikronisiertes eplerenon
US5055306A (en)	1991-10-08	Sustained-release formulations
US4904478A (en)	1990-02-27	Slow-release sodium fluoride tablet and method for treatment of osteoporosis
DE69820287T2 (de)	2004-10-14	Pharmazeutische Zubereitung, die Chlodronat als Wirkstoff und silicifizierte mikrokristalline Cellulose als Exipienten umfasst
DE4225730C2 (de)	2003-04-30	Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
TW576743B (en)	2004-02-21	Extended release formulations of erythromycin derivatives
DE69837610T2 (de)	2008-01-03	Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird in verzögert freigesetzter form und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung
DE3880762T2 (de)	1993-09-23	Orale, acetaminophen enthaltende zusammensetzung mit gesteuerter arzneistoff-freisetzung und verfahren zu ihrer herstellung.
DE3879080T2 (de)	1993-07-15	Pharmazeutische matrix mit verzoegerter freisetzung und verfahren.
IE53543B1 (en)	1988-12-07	New oral dipyridamole preparations
JPH0122245B2 (fr)	1989-04-25
CZ287378B6 (en)	2000-11-15	Pharmaceutical preparation containing fluoxetine and process for preparing thereof
JPS63107917A (ja)	1988-05-12	イブプロフエン徐放性製剤およびその製造方法
AU748359B2 (en)	2002-06-06	Controlled-release formulations
DE69929703T2 (de)	2007-02-22	Neue orale formulierungen für 5-ht4 agonisten oder antagonisten
EP1509207B1 (fr)	2009-04-29	Composition pharmaceutique à base d'oxcarbazepine, à libération retard du principe actif
CN109010361B (zh)	2019-05-14	碳酸钙维生素d3制剂及其制备方法
KR20070043714A (ko)	2007-04-25	칼슘-함유 화합물 및 당알코올을 포함하는 입상체
US5650168A (en)	1997-07-22	Tablet with improved bioavailability containing dichloromethylenediphosphonic acid as the active substance
DE60225686T2 (de)	2009-04-16	Paracetamol enthaltende tablette
DE60013466T2 (de)	2005-01-20	Im mund zerfallende zusammensetzung mit mirtazapin
JP2020536931A (ja)	2020-12-17	二層医薬錠剤製剤
US4859467A (en)	1989-08-22	Sustained release fluoride composition
US5013728A (en)	1991-05-07	Composition for treating osteoporosis and hormonal imbalance
DE69816124T2 (de)	2004-05-06	Pharmazeutische zusammensetzungen enthaltend zafirlukast